Allarity Therapeutics, Inc. 8-K

What Happened
Allarity Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025 in a press release issued on March 31, 2026. The company filed a Form 8-K (Item 2.02) to disclose that press release; the release itself is attached to the filing as Exhibit 99.1. The 8-K states the press release is being furnished and is not to be deemed “filed” for purposes of Section 18 of the Exchange Act.

Key Details

• Press release announcing fiscal 2025 results was issued on March 31, 2026.
• Financial period covered: fiscal year ended December 31, 2025.
• The press release is included with the 8-K as Exhibit 99.1.
• The filing notes the information furnished is not incorporated by reference into other filings unless specifically stated.

Why It Matters
This filing signals that Allarity has publicly released its full-year 2025 earnings and other financial metrics; investors should read the attached press release (Exhibit 99.1) for specific results such as revenue, net income/loss, cash position, and any management commentary or guidance. The 8-K itself does not include the numeric details — it only documents that the company issued the results — so review the press release to assess the company’s recent financial performance.